Opus Genetics, Inc. Increase (Decrease) in Accounts Receivable
Opus Genetics, Inc. (IRD) reported Increase (Decrease) in Accounts Receivable of -$954.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Opus Genetics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$690.00K, a 316.30% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$264.00K.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$921.00K, a 153.99% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$483.00K, a 196.79% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$1.57M, a 159.46% decline from fiscal 2024.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $2.64M.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$372.00K, a 128.66% decline from fiscal 2022.
- Opus Genetics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $1.30M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$690.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$954.00K 10-Q · filed 2026-08-06 | -$1.88M derived: sum of 3 quarters · filed 2026-08-06 | -$2.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$264.00K 10-Q · filed 2026-05-12 | -$1.19M derived: sum of 2 quarters · filed 2026-05-12 | -$1.67M derived: sum of 3 quarters · filed 2026-05-12 | -$1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$921.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.40M derived: sum of 2 quarters · filed 2026-03-12 | -$1.08M derived: sum of 3 quarters · filed 2026-08-06 | -$1.57M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$164.00K derived: sum of 2 quarters · filed 2026-08-06 | -$647.00K 10-Q · filed 2025-11-12 | $1.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$164.00K 10-Q · filed 2026-08-06 | $1.54M derived: sum of 3 quarters · filed 2026-08-06 | $2.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$483.00K 10-Q · filed 2026-05-12 | $1.22M derived: sum of 2 quarters · filed 2026-05-12 | $1.72M derived: sum of 3 quarters · filed 2026-05-12 | $1.16M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.21M derived: sum of 2 quarters · filed 2026-03-12 | $1.64M derived: sum of 3 quarters · filed 2026-03-12 | $2.64M 10-K · filed 2026-03-12 |
| 2024-09-30 | $499.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$67.00K derived: sum of 2 quarters · filed 2025-11-12 | $931.00K 10-Q · filed 2025-11-12 | -$8.28M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$566.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $432.00K 10-Q · filed 2025-08-13 | -$8.77M derived: sum of 3 quarters · filed 2025-08-13 | $1.22M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $998.00K 10-Q · filed 2025-05-15 | -$8.21M derived: sum of 2 quarters · filed 2025-05-15 | $1.79M derived: sum of 3 quarters · filed 2025-05-15 | -$910.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $791.00K derived: sum of 2 quarters · filed 2025-03-31 | -$1.91M derived: sum of 3 quarters · filed 2025-03-31 | -$372.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.30M derived: sum of 2 quarters · filed 2024-11-12 | $8.83M 10-Q · filed 2024-11-12 | $10.13M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.16M 10-Q · filed 2024-08-13 | $135.00K derived: sum of 3 quarters · filed 2024-08-13 | $135.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.54M 10-Q · filed 2024-05-10 | $2.83M derived: sum of 2 quarters · filed 2024-05-10 | $2.83M derived: sum of 3 quarters · filed 2024-05-10 | $2.83M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.30M derived: sum of 2 quarters · filed 2024-03-08 | $1.30M derived: sum of 3 quarters · filed 2024-03-08 | $1.30M 10-K · filed 2024-03-08 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 | |||
| 2021-06-30 | $50.00K 10-Q · filed 2022-08-12 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |